Yongli Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongli Yang has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Pengpeng Wang
Department of Occupational and Environmental Health, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China
7 shared publicationsWu Yao
Department of Occupational and Environmental Health, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China
7 shared publicationsXiaolei Feng
Department of Occupational and Environmental Health, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China
7 shared publicationsTuanwei Wang
Department of Occupational and Environmental Health, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China
6 shared publicationsWei Wang
Department of Occupational and Environmental Health, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; The Key Laboratory of Nanomedicine and Health Inspection of Zhengzhou, Zhengzhou, China
6 shared publicationsMingcui Ding
Department of Occupational and Environmental Health, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China
5 shared publications
Latest Publications
- Open Access
Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467
The authors would like to make the following corrections to this published paper
Open AccessCorrection: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467
The authors would like to make the following corrections to this published paper
- Open Access
The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial
Background: Influenza is a serious contagious disease caused by influenza virus. It is particularly dangerous for children, potentially leading to severe and even fatal complications. The aim of this study was to evaluate the safety and immunogenicity of two candidate quadrivalent influenza subunit vaccines in children aged 6–35 months. Methods: The subjects were randomly divided into three groups at a 1:1:1 ratio and received the corresponding vaccines: QIV-Sub-HD (Quadrivalent Influenza Subunit Vaccine, High Dose), QIV-Sub-LD (Quadrivalent Influenza Subunit Vaccine, Low Dose) and QIV-Split-LD (Quadrivalent Influenza Split-Virion Vaccine, Low Dose). Adverse events were recorded at 30 min, 0–7 days and 8–28 and 30 days after each dose of immunization. Serious adverse events (SAEs) were collected and reported within 6 months after the full vaccination. Blood samples were collected before the first dose and on 28 days, 3 months and 6 months after full vaccination for antibody detection to evaluate the immunogenicity and duration of immune responses. Results: The results showed that the relative and absolute criteria met the goals set by the clinical trial protocol, indicating that both vaccines are immunogenic. From the first dose to 30 days after full vaccination, the total incidence of adverse reactions in the QIV-Sub-HD, QIV-Sub-LD and QIV-Split-LD groups was 29.64%, 33.33% and 29.64%, respectively. The main symptoms were fever, cough, diarrhea and vomiting. No new safety concerns were identified. Conclusions: The quadrivalent influenza subunit vaccines candidate, manufactured by Ab&B Bio-tech Co., Ltd. JS., are safe and immunogenic in children aged 6–35 months.
Open AccessThe Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial
Background: Influenza is a serious contagious disease caused by influenza virus. It is particularly dangerous for children, potentially leading to severe and even fatal complications. The aim of this study was to evaluate the safety and immunogenicity of two candidate quadrivalent influenza subunit vaccines in children aged 6–35 months. Methods: The subjects were randomly divided into three groups at a 1:1:1 ratio and received the corresponding vaccines: QIV-Sub-HD (Quadrivalent Influenza Subunit Vaccine, High Dose), QIV-Sub-LD (Quadrivalent Influenza Subunit Vaccine, Low Dose) and QIV-Split-LD (Quadrivalent Influenza Split-Virion Vaccine, Low Dose). Adverse events were recorded at 30 min, 0–7 days and 8–28 and 30 days after each dose of immunization. Serious adverse events (SAEs) were collected and reported within 6 months after the full vaccination. Blood samples were collected before the first dose and on 28 days, 3 months and 6 months after full vaccination for antibody detection to evaluate the immunogenicity and duration of immune responses. Results: The results showed that the relative and absolute criteria met the goals set by the clinical trial protocol, indicating that both vaccines are immunogenic. From the first dose to 30 days after full vaccination, the total incidence of adverse reactions in the QIV-Sub-HD, QIV-Sub-LD and QIV-Split-LD groups was 29.64%, 33.33% and 29.64%, respectively. The main symptoms were fever, cough, diarrhea and vomiting. No new safety concerns were identified. Conclusions: The quadrivalent influenza subunit vaccines candidate, manufactured by Ab&B Bio-tech Co., Ltd. JS., are safe and immunogenic in children aged 6–35 months.
- Open Access
- 2 November 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 8 (11) , 146
Better Medications Adherence Lowers Cardiovascular Events, Stroke, and All-Cause Mortality Risk: A Dose-Response Meta-Analysis
Aims: We investigated the association between vascular medication adherence, assessed by different methods, and the risk of cardio-cerebrovascular events and all-cause mortality. Methods: A meta-analysis with a systematic search of PubMed, Web of Science, EMBASE, and Cochrane databases from inception date to 21 June 2021 was used to identify relevant studies that had evaluated the association between cardiovascular medication adherence levels and cardiovascular events (CVEs), stroke, and all-cause mortality risks. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects meta-analysis. Restricted cubic splines were used to model the dose-response association. Results: We identified 46 articles in the dose-response meta-analysis. The dose-response analysis indicated that a 20% increment in cardiovascular medication, antihypertensive medication, and lipid-lowering medication adherence level were associated with 9% (RR: 0.91, 95% CI 0.88–0.94), 7% (RR 0.93, 95% CI: 0.84–1.03), and 10% (RR 0.90, 95% CI: 0.88–0.92) lowers risk of CVEs, respectively. The reduced risk of stroke respectively was 16% (RR: 0.84, 95% CI: 0.81–0.87), 17% (RR 0.83, 95% CI: 0.78–0.89), and 13% (RR 0.87, 95% CI: 0.84–0.91). The reduced risk of all-cause mortality respectively was 10% (RR: 0.90, 95% CI: 0.87–0.92), 12% (RR 0.88, 95% CI: 0.82–0.94), and 9% (RR 0.91, 95% CI: 0.89–0.94). Conclusions: A better medication adherence level was associated with a reduced risk of cardio-cerebrovascular events and all-cause mortality.
- 2 November 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 8 (11) , 146
Open AccessBetter Medications Adherence Lowers Cardiovascular Events, Stroke, and All-Cause Mortality Risk: A Dose-Response Meta-Analysis
Aims: We investigated the association between vascular medication adherence, assessed by different methods, and the risk of cardio-cerebrovascular events and all-cause mortality. Methods: A meta-analysis with a systematic search of PubMed, Web of Science, EMBASE, and Cochrane databases from inception date to 21 June 2021 was used to identify relevant studies that had evaluated the association between cardiovascular medication adherence levels and cardiovascular events (CVEs), stroke, and all-cause mortality risks. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects meta-analysis. Restricted cubic splines were used to model the dose-response association. Results: We identified 46 articles in the dose-response meta-analysis. The dose-response analysis indicated that a 20% increment in cardiovascular medication, antihypertensive medication, and lipid-lowering medication adherence level were associated with 9% (RR: 0.91, 95% CI 0.88–0.94), 7% (RR 0.93, 95% CI: 0.84–1.03), and 10% (RR 0.90, 95% CI: 0.88–0.92) lowers risk of CVEs, respectively. The reduced risk of stroke respectively was 16% (RR: 0.84, 95% CI: 0.81–0.87), 17% (RR 0.83, 95% CI: 0.78–0.89), and 13% (RR 0.87, 95% CI: 0.84–0.91). The reduced risk of all-cause mortality respectively was 10% (RR: 0.90, 95% CI: 0.87–0.92), 12% (RR 0.88, 95% CI: 0.82–0.94), and 9% (RR 0.91, 95% CI: 0.89–0.94). Conclusions: A better medication adherence level was associated with a reduced risk of cardio-cerebrovascular events and all-cause mortality.
- Open Access
- 24 February 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, e57
The factors associated with natural disease progression from HIV to AIDS in the absence of ART, a propensity score matching analysis
This study aimed at comparing the factors associated with the natural progression between typical progressors (TPs) and rapid progressors (RPs) in HIV-infected individuals. A retrospective study was conducted on 2095 eligible HIV-infected individuals from 1995 to 2016 in a high-risk area of Henan Province, China. Propensity score matching was used to balance covariates, and the conditional logistic regression analyses were performed to explore the factors of natural disease progression among HIV infectors. A total of 379 pairs of RPs and TPs were matched. The standardised difference values of all covariates were less than 10%. HIV-infected individuals transmitted through sexual transmission (odds ratio (OR) 0.56, 95% confidence interval (CI) 0.36–0.85) were more likely to progress to AIDS compared with those infected through contaminated blood. Older age at diagnosis of HIV-infected individuals (OR 0.72, 95% CI 0.58–0.89) exhibited a faster progression to AIDS. HIV-infected individuals identified through a unique survey (OR 7.01, 95% CI 2.99–16.44) were less likely to progress to AIDS compared with those identified through medical institutions. HIV-infected individuals who had higher baseline CD4+T cell counts (OR 3.37, 95% CI 2.59–4.38) had a slower progression to AIDS. These findings provide evidence for natural disease progression from HIV to AIDS between TPs and RPs.
- 24 February 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, e57
Open AccessThe factors associated with natural disease progression from HIV to AIDS in the absence of ART, a propensity score matching analysis
This study aimed at comparing the factors associated with the natural progression between typical progressors (TPs) and rapid progressors (RPs) in HIV-infected individuals. A retrospective study was conducted on 2095 eligible HIV-infected individuals from 1995 to 2016 in a high-risk area of Henan Province, China. Propensity score matching was used to balance covariates, and the conditional logistic regression analyses were performed to explore the factors of natural disease progression among HIV infectors. A total of 379 pairs of RPs and TPs were matched. The standardised difference values of all covariates were less than 10%. HIV-infected individuals transmitted through sexual transmission (odds ratio (OR) 0.56, 95% confidence interval (CI) 0.36–0.85) were more likely to progress to AIDS compared with those infected through contaminated blood. Older age at diagnosis of HIV-infected individuals (OR 0.72, 95% CI 0.58–0.89) exhibited a faster progression to AIDS. HIV-infected individuals identified through a unique survey (OR 7.01, 95% CI 2.99–16.44) were less likely to progress to AIDS compared with those identified through medical institutions. HIV-infected individuals who had higher baseline CD4+T cell counts (OR 3.37, 95% CI 2.59–4.38) had a slower progression to AIDS. These findings provide evidence for natural disease progression from HIV to AIDS between TPs and RPs.
- 1 October 2019
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 182, 109453
Benchmark dose assessment for coke oven emissions-induced telomere length effects in occupationally exposed workers in China
- 1 October 2019
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 182, 109453
Benchmark dose assessment for coke oven emissions-induced telomere length effects in occupationally exposed workers in China
- 12 August 2019
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part B
- Vol. 54 (12) , 948-953
Telomere length in workers was effected by omethoate exposure and interaction between smoking and p21 polymorphisms
Omethoate is an organophosphorus pesticide that poses a major health hazard, especially DNA damage. The purpose of this study was to investigate the factors affecting telomere length in workers exposed to omethoate by analyzing the interaction between cell cycle gene polymorphism and environmental factors. The exposure group consisted of 118 workers exposed to omethoate for 8–10 years, the control group comprised 115 healthy people without occupational toxicant exposure history. The telomere length of genomic DNA from peripheral blood leucocyte was determined with real-time PCR. Polymerase chain reaction and restriction fragment length polymorphism was used to detect the polymorphisms in p53, p21 and MDM2 gene. The telomere length in the (CA + AA) genotypes for p21 rs1801270 polymorphism was longer than that in the CC genotype in control group (P = 0.015). The generalized linear model analysis indicated the interaction of the p21 rs1801270 polymorphic (CA + AA) genotypes and smoking has a significant effect on telomere length (β = −0.258, P = 0.085). The prolongation of telomere length in omethoate-exposed workers was associated with genotypes (CA + AA) of p21 rs1801270, and interactions of (CA + AA) genotypes and smoking factor.
- 12 August 2019
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part B
- Vol. 54 (12) , 948-953
Telomere length in workers was effected by omethoate exposure and interaction between smoking and p21 polymorphisms
Omethoate is an organophosphorus pesticide that poses a major health hazard, especially DNA damage. The purpose of this study was to investigate the factors affecting telomere length in workers exposed to omethoate by analyzing the interaction between cell cycle gene polymorphism and environmental factors. The exposure group consisted of 118 workers exposed to omethoate for 8–10 years, the control group comprised 115 healthy people without occupational toxicant exposure history. The telomere length of genomic DNA from peripheral blood leucocyte was determined with real-time PCR. Polymerase chain reaction and restriction fragment length polymorphism was used to detect the polymorphisms in p53, p21 and MDM2 gene. The telomere length in the (CA + AA) genotypes for p21 rs1801270 polymorphism was longer than that in the CC genotype in control group (P = 0.015). The generalized linear model analysis indicated the interaction of the p21 rs1801270 polymorphic (CA + AA) genotypes and smoking has a significant effect on telomere length (β = −0.258, P = 0.085). The prolongation of telomere length in omethoate-exposed workers was associated with genotypes (CA + AA) of p21 rs1801270, and interactions of (CA + AA) genotypes and smoking factor.
- 1 August 2019
- Published by Elsevier in Environmental Toxicology and Pharmacology
- Vol. 70, 103197
The interaction effects of coke oven emissions exposure and metabolic enzyme Gene variants on total antioxidant capacity of workers
- 1 August 2019
- Published by Elsevier in Environmental Toxicology and Pharmacology
- Vol. 70, 103197
The interaction effects of coke oven emissions exposure and metabolic enzyme Gene variants on total antioxidant capacity of workers
- Open Access
- 28 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 563973
Identification of 67 pleiotropic genes for seven autoimmune diseases using multivariate statistical analysis
Although genome-wide association studies (GWAS) have a dramatic impact on susceptibility locus discovery, this univariate approach has limitation in detecting complex genotype-phenotype correlations. It is essential to identify shared genetic risk factors acting through common biological mechanisms of autoimmune diseases with a multivariate analysis. In this study, the GWAS summary statistics including 41,274 single nucleotide polymorphisms (SNPs) located in 11,516 gene regions was analyzed to identify shared variants of seven autoimmune diseases using metaCCA method. Gene-based association analysis was used to refine the pleiotropic genes. In addition, GO term enrichment analysis and protein-protein interaction network analysis were applied to explore the potential biological function of the identified genes. After metaCCA analysis, 4,962 SNPs (P−6) and 1,044 pleotropic genes (P−6) were identified. By screening the results of gene-based p-values, we identified the existence of 27 confirmed pleiotropic genes and highlighted 40 novel pleiotropic genes which achieved significance threshold in metaCCA analysis and were also associated with at least one autoimmune disease in the VEGAS2 analysis. The metaCCA method could identify novel variants associated with complex diseases incorporating different GWAS datasets. Our analysis may provide insights for some common therapeutic approaches of autoimmune diseases based on the pleiotropic genes and common mechanisms identified.Author summary: Although previous researches have clearly indicated varying degrees of overlapping genetic sensitivities in autoimmune diseases, it has proven GWAS only explain small percent of heritability. Here, we take advantage of recent technical and methodological advances to identify pleiotropic genes that act on common biological mechanisms and the overlapping pathophysiological pathways of autoimmune diseases. After selection using multivariate analysis and verification using gene-based analyses, we successfully identified a total of 67 pleiotropic genes and performed the functional term enrichment analysis. In particularly, 27 genes were identified to be pleiotropic in previous different types of studies, which were validated by our present study. Forty significant genes (16 genes were associated with one disease earlier, and 24 were novel) might be the novel pleiotropic candidate genes for seven autoimmune diseases. The improved detection not only yielded the shared genetic components but also provided better understanding for exploring the potential common biological pathogenesis of these major autoimmune diseases.
- 28 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 563973
Open AccessIdentification of 67 pleiotropic genes for seven autoimmune diseases using multivariate statistical analysis
Although genome-wide association studies (GWAS) have a dramatic impact on susceptibility locus discovery, this univariate approach has limitation in detecting complex genotype-phenotype correlations. It is essential to identify shared genetic risk factors acting through common biological mechanisms of autoimmune diseases with a multivariate analysis. In this study, the GWAS summary statistics including 41,274 single nucleotide polymorphisms (SNPs) located in 11,516 gene regions was analyzed to identify shared variants of seven autoimmune diseases using metaCCA method. Gene-based association analysis was used to refine the pleiotropic genes. In addition, GO term enrichment analysis and protein-protein interaction network analysis were applied to explore the potential biological function of the identified genes. After metaCCA analysis, 4,962 SNPs (P−6) and 1,044 pleotropic genes (P−6) were identified. By screening the results of gene-based p-values, we identified the existence of 27 confirmed pleiotropic genes and highlighted 40 novel pleiotropic genes which achieved significance threshold in metaCCA analysis and were also associated with at least one autoimmune disease in the VEGAS2 analysis. The metaCCA method could identify novel variants associated with complex diseases incorporating different GWAS datasets. Our analysis may provide insights for some common therapeutic approaches of autoimmune diseases based on the pleiotropic genes and common mechanisms identified.Author summary: Although previous researches have clearly indicated varying degrees of overlapping genetic sensitivities in autoimmune diseases, it has proven GWAS only explain small percent of heritability. Here, we take advantage of recent technical and methodological advances to identify pleiotropic genes that act on common biological mechanisms and the overlapping pathophysiological pathways of autoimmune diseases. After selection using multivariate analysis and verification using gene-based analyses, we successfully identified a total of 67 pleiotropic genes and performed the functional term enrichment analysis. In particularly, 27 genes were identified to be pleiotropic in previous different types of studies, which were validated by our present study. Forty significant genes (16 genes were associated with one disease earlier, and 24 were novel) might be the novel pleiotropic candidate genes for seven autoimmune diseases. The improved detection not only yielded the shared genetic components but also provided better understanding for exploring the potential common biological pathogenesis of these major autoimmune diseases.
- Open Access
- 1 January 2019
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (21) , 5090-5098
Diagnostic Value of Plasma MicroRNAs for Lung Cancer Using Support Vector Machine Model
Aim: Small single-stranded non-coding RNAs (miRNAs) play an important role in carcinogenesis through degrading target mRNAs. However, the diagnostic value of miRNAs was not explored in lung cancers. In this study, a support-vector-machine (SVM) model for diagnosis of lung cancer was established based on plasma miRNAs biomarkers, clinical symptoms and epidemiology material.
- 1 January 2019
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (21) , 5090-5098
Open AccessDiagnostic Value of Plasma MicroRNAs for Lung Cancer Using Support Vector Machine Model
Aim: Small single-stranded non-coding RNAs (miRNAs) play an important role in carcinogenesis through degrading target mRNAs. However, the diagnostic value of miRNAs was not explored in lung cancers. In this study, a support-vector-machine (SVM) model for diagnosis of lung cancer was established based on plasma miRNAs biomarkers, clinical symptoms and epidemiology material.